This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allavena, P. Articles by Mantovani, A. Search for Related Content PubMed PubMed Citation Articles by Allavena, P. Articles by Mantovani, A.

Intraperitoneal Recombinant -Interferon in Patients with Recurrent Ascitic Ovarian Carcinoma: Modulation of Cytotoxicity and Cytokine Production in Tumor-associated Effectors and of Major Histocompatibility Antigen Expression on Tumor Cells¹

Laboratory of Immunology, "Mario Negri" Institute, Milan, Italy [P. A., F. P., D. M., A. E., M. S., A. M.]; Department of Gynecology Oncology, S. Gerardo Hospital, Monza, Italy [N. C., A. L., C. M.]; and Biogen S. A., Geneva, Switzerland [A. G., W. M.]

Seven patients with advanced epithelial carcinoma and ascites, relapsing after two or more regimens of standard chemotherapy, have been treated with recombinant -interferon (rIFN-) i.p., via a permanent catheter. rIFN- (Immuneron; Biogen; 0.5 mg = 10⁷ IU in 2 liters of saline) was administered 3 times a week, on alternate weeks, for a total of nine courses. No major toxicities were observed: mild fever, malaise, and a flu-like syndrome occurred in all patients.

The modulation of immunological parameters was studied. Cytotoxic activity of immunocompetent cells against tumor cell lines was measured both in the peritoneal compartment and in peripheral blood mononuclear cells. A significant increase of cytotoxicity of tumor-associated macrophages was observed in 5 of 7 patients and in 4 of 7 patients with tumor-associated peritoneal lymphocytes. Circulating effector cells were only occasionally stimulated. Tumor-associated macrophages isolated from the ascitic fluid and stimulated with lipopolysaccharide produced higher amounts of interleukin 1 in 5 of 6 patients tested, while interleukin 6 production by unstimulated tumor-associated macrophages was augmented in 2 of 2 patients after rIFN- treatment.

Freshly isolated ovarian carcinoma cells from the ascitic fluid had a variable, although usually low, expression of HLA-DR antigens. rIFN- treatment caused a marked increase in HLA-DR expression in all patients tested. Expression of HLA class I antigens was negative in 2 of 5 patients and was strongly increased in 1 of the 2 after treatment.

The observation that rIFN- administered i.p. activates in situ effector cells and augments major histocompatibility antigen expression in tumor cells, with minimal toxicity, encourages further efforts to investigate its therapeutic potential in ovarian carcinoma.

¹ This work was supported in part by Ministero Ricerca Scientifica Program Italy-USA on Cancer Therapy.

² Present address: Ares Serono, Geneva, Switzerland.

³ Present address: Domaine de Pins A, Vaud, 1196 Switzerland.

Received 4/27/90. Accepted 8/ 1/90.

This article has been cited by other articles:

				C. S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M. L. Hensley, D. R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission Clin. Cancer Res., May 1, 2008; 14(9): 2740 - 2748. [Abstract] [Full Text] [PDF]

				P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, F. Marchesi, C. O. Olimpio, C. Bonardi, A. Garbi, A. Lissoni, et al. Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production Cancer Res., April 1, 2005; 65(7): 2964 - 2971. [Abstract] [Full Text] [PDF]

				J. S. Berek, B. C. Schultes, and C. F. Nicodemus Biologic and Immunologic Therapies for Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 168s - 174. [Abstract] [Full Text] [PDF]

				R. S. Freedman, A. P. Kudelka, J. J. Kavanagh, C. Verschraegen, C. L. Edwards, M. Nash, L. Levy, E. N. Atkinson, H.-Z. Zhang, B. Melichar, et al. Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-{{gamma}} and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma Clin. Cancer Res., June 1, 2000; 6(6): 2268 - 2278. [Abstract] [Full Text]